Urinary System - Level 2.2 Flashcards
Pathology of bladder cancer?
o Calyces, renal pelvis, ureter, bladder and urethras lined by transitional epithelium
o 50% in bladder
Spread of bladder cancer?
o Local – pelvic structures
o Lymph – iliac and para-aortic nodes
o Bloods – liver and lungs
Epidemiology of bladder cancer?
- Men > Women
- Age >40
Cell types of bladder cancer?
o 90% transitional cell carcinoma
o Rare – adenocarcinoma, SCC (from schistosomiasis)
Aetiology of bladder cancer?
o Cigarette smoking o Aromatic amines (rubber industry) o Chronic cystitis o Drugs – cyclophosphamide o Schistosomiasis (SCC)
Symptoms of bladder cancer?
o Painless haematuria o UTI symptoms without bacteriuria o Pain o Voiding irritability o If in ureters, pelvis – flank pain due to obstruction
When to refer on 2 week pathway of bladder cancer?
Over 45 with:
• Unexplained visible haematuria without UTI OR
• Visible haematuria persisting or recurring after treatment of UTI
Over 60 with unexplained non-visible haematuria and either:
• Dysuria OR
• Raised WCC
When to refer non-urgently of bladder cancer?
o Non-urgent referral in over 60 with recurrent or persistent UTIs
Diagnostic investigations performed in secondary care of bladder cancer?
US KUB
Cystoscopy with biopsy
If invasive – CT/MRI
Transurethral Resection of bladder tumour
• With photodynamic diagnosis, narrow-band imaging, cytology or urinary biomarker test
• Obtain detrusor muscle
• Record size and number of tumours
• Offer single dose of intravesical mitomycin C
Staging investigations of bladder cancer?
TURBT within 6 weeks if no detrusor muscle
CT scan
• If diagnosed with muscle-invasive or high-risk and being assessed for radical treatment
CT urography
CT thorax
PET scan – if indeterminate findings on CT or high risk of metastatic disease
Management of bladder cancer - general advice?
o Clinical nurse specialist – support
o Smoking cessation
Management of bladder cancer - non-muscle invasive - risk classification?
o Risk Classification – determined on size, number, histology, type, grade, stage
Management of bladder cancer - non-muscle invasive - low risk?
White-light guided TURBT
o With photodynamic diagnosis, narrow-band imaging, cytology or urinary biomarker test
o Obtain detrusor muscle
o Record size and number of tumours
o Offer single dose of intravesical mitomycin C
o TURBT within 6 weeks if no detrusor muscle
Follow-Up
o Cystoscopy at 3 months and 12 months after diagnosis
o Discharge if no recurrence
Management of bladder cancer - non-muscle invasive - medium risk?
6 doses of intravesical mitomycin C
o If recurs, specialist MDT
Follow Up
o Cystoscopy follow up at 3, 9 and 18 months and annually after
Management of bladder cancer - non-muscle invasive - high risk?
TURBT before 6 weeks – if 1st TURBT shows high risk
Intravesical BCG or
o Induction and maintenance
Radical cystectomy
o Urinary stoma or urinary diversion (unless cognitive impairment, impaired renal function or bowel disease)
Follow Up o Cystoscopy every 3 months for 2 years, every 6 months for 2 years and then annually o CT every 6 months for 2 years o Annually Measure eGFR US of KUB B12 and folate level Urethral washing for cytology
Management of bladder cancer - muscle invasive?
Neoadjuvant Chemotherapy – cisplatin then:
Radical Cystectomy OR
• Urinary stoma or urinary diversion (unless cognitive impairment, impaired renal function or bowel disease)
• Adjuvant chemotherapy - cisplatin
Radiotherapy with Radiosensitiser
• Mitomycin in combo with 5-FU
• Over 6.5 or 4 weeks
Follow up Cystoscopy every 3 months for 2 years, every 6 months for 2 years and then annually CT every 6 months for 2 years Annually • Measure eGFR • US of KUB • B12 and folate level • Urethral washing for cytology
Management of bladder cancer - locally advance or metastatic cancer?
Chemotherapy
MVAC with G-CSF (if ECOG 0,1 and GFR >60)
• Carboplatin with gemcitabine (if ECOG 2 or GFR<60)
• Pembrolizumab if cisplatin unsuitable
Gemcitabine with MVAC and G-CSF
Management of bladder cancer - symptoms management?
Bladder (haematuria, dysuria, frequency, nocturia)
• Radiotherapy
Loin Pain or Renal Failure
• Percutaneous nephrostomy or retrograde stenting
Bleeding
• Radiotherapy or embolization
Pelvic Pain
• Radiotherapy
• Nerve block
• Palliative chemotherapy
Type of prostate cancer?
- Malignant tumour of the prostate
o >95% are adenocarcinomas, developing in glandular tissue in posterior or peripheral parts of prostate - BPH more common in centre of gland
Spread of prostate cancer?
- Spread may be local (seminal vesicles, bladder, rectum), via lymph or haematogenous (sclerotic bony lesions)
Epidemiology of prostate cancer?
- Commonest cancer in males
- 1 in 8 men will get prostate cancer in lives
- Older men - >50% occur after 75 years
Risk factors of prostate cancer?
o Genetics BRCAII & pTEN genes o Radiation exposure o Diet o Anabolic Steroids (due to increased testosterone) o Age o African/Afro-Caribbean o Family History
Symptoms of prostate cancer?
o Asymptomatic o Poor stream o Nocturia o Terminal dribbling o Polyuria o Metastatic symptoms Weight loss, anaemia, lower back pain, MSCC
Signs of prostate cancer?
o Rectal Examination
Enlarged, hard, craggy gland
Loss of median sulcus